Palatin Technologies Inc

PTN

Company Profile

  • Business description

    Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.

  • Contact

    301 Carnegie Center Drive
    Suite 304
    PrincetonNJ08540
    USA

    T: +1 609 495-2200

    E: [email protected]

    https://www.palatin.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    25

Stocks News & Analysis

stocks

CBA earnings: Business lending powers on, but costs and credit bear watching

Our view after the bank reports first quarter earnings.
stocks

Apple earnings review: Revenue beats estimates as memory crunch threatens margins

Apple shares are trading at record highs after posting solid results.
stocks

Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil

We’re reducing our long-term revenue estimates.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,204.5069.70-0.75%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,637.60370.95-1.55%
NASDAQ25,136.27229.82-0.91%
Nikkei 22561,142.35322.990.53%
NZX 50 Index14,142.6531.03-0.22%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,082.2064.60-0.71%
SSE Composite Index3,634.3521.48-0.59%

Market Movers